Tildrakizumab
Intervention1 paper1 finding
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
1 of 1 finding with company ties
- Human trial1
Outcomes
1GrimAge
downin humans1
1 study
GrimAge
downin humans1
Tildrakizumab decreases GrimAge in humans (-0.3 years at week 28, -0.5 years at week 52).
Human trialmoderate-to severe psoriasisblood100 mg52-week
The effects of tildrakizumab in the epigenetic aging deviation of psoriasis: A 52-week open-label study · Journal of the American Academy of Dermatology · 19 Aug 2026